APA (7th ed.) Citation

Mease, P. J., Marzo-Ortega, H., Poder, A., Van den Bosch, F., Wollenhaupt, J., Lespessailles, E., . . . Hall, S. (2018). 165 Apremilast, an oral phosphodiesterase-4 inhibitor, is associated with long-term (156-week) improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in subjects with psoriatic arthritis: Pooled results from three phase III randomised controlled trials. Rheumatology (Oxford, England), 57(suppl_3), . https://doi.org/10.1093/rheumatology/key075.389

Chicago Style (17th ed.) Citation

Mease, Philip J., Helena Marzo-Ortega, Airi Poder, Filip Van den Bosch, Jurgen Wollenhaupt, Eric Lespessailles, Lichen Teng, and Stephen Hall. "165 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, Is Associated with Long-term (156-week) Improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in Subjects with Psoriatic Arthritis: Pooled Results from Three Phase III Randomised Controlled Trials." Rheumatology (Oxford, England) 57, no. suppl_3 (2018). https://doi.org/10.1093/rheumatology/key075.389.

MLA (9th ed.) Citation

Mease, Philip J., et al. "165 Apremilast, an Oral Phosphodiesterase-4 Inhibitor, Is Associated with Long-term (156-week) Improvements in Bath Ankylosing Spondylitis Disease Activity Index Score in Subjects with Psoriatic Arthritis: Pooled Results from Three Phase III Randomised Controlled Trials." Rheumatology (Oxford, England), vol. 57, no. suppl_3, 2018, https://doi.org/10.1093/rheumatology/key075.389.